Is Sun Pharma Advanced Research Company a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company .

Is Sun Pharma Advanced Research Company undervalued or overvalued?

The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Sun Pharma Advanced Research Company share price return in the past 10 years?

Sun Pharma Advanced Research Company Ltd share price has appreciated 0.6% annually (CAGR) over the past ten years.

Is Sun Pharma Advanced Research Company a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Sun Pharma Advanced Research Company?

The latest standalone P/E ratio of Sun Pharma Advanced Research Company as of 08-Nov-2024 is 0.00.

What is the P/B ratio of Sun Pharma Advanced Research Company?

The latest standalone P/B ratio of Sun Pharma Advanced Research Company as of 08-Nov-2024 is -84.01.

What is the 52-week high and low of Sun Pharma Advanced Research Company?

The 52-week high of Sun Pharma Advanced Research Company is Rs. 474.00 and the 52-week low is Rs. 196.45.

Sun Pharma Advanced Research Company Ltd - Stock Valuation and Financial Performance

Name: Sun Pharma Advanced Research Company
Brand: Sun Pharma Advanced Research Company

BSE: 532872 | NSE: SPARC | Business Support | Small Cap

Place order

Sun Pharma Adv. Res Share Price

₹206.25 -5.85 -2.76%
as on 08-Nov'24 00:00

10 Year X-Ray of Sun Pharma Adv. Res:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	24%	-31.7%	-71.4%	-94.7%	-113.1%	-60%	-179%	-254.1%	-225.6%	-69.4%	-
Value Creation Index ⓘ	0.7	-3.3	-6.3	-8.0	-9.4	-5.3	NA	NA	NA	-6.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	167	156	161	181	78.3	183	76.8	253	137	239	60
Sales YoY Gr.	-	-6.8%	3.6%	12.2%	-56.8%	133.7%	-58%	229.3%	-45.7%	74%	-
Adj EPS ⓘ	1.1	-1.7	-3	-4.9	-9.3	-5.5	-11.8	-5.9	-7.6	-6.8	-12.7
YoY Gr.	-	-252.3%	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	5.8	4.2	1.2	6.4	3.7	11.3	-0.7	-6.4	-7.5	15.8	-2.5
Adj Net Profit ⓘ	26.1	-39.6	-69.8	-120	-234	-144	-309	-153	-206	-221	-411
Cash Flow from Ops. ⓘ	36.9	-41.2	-44.2	-128	-183	-172	-211	-152	-208	-69.1	-
Debt/CF from Ops. ⓘ	0.1	-0.1	-1.3	-0	-0	-0	-0.3	-1.5	-0.4	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	4.1%	25%	46%	74%
Adj EPS ⓘ	-222.6%	NA	NA	NA
BVPSⓘ	11.7%	33.6%	NA	NA
Share Price	0.6%	5.6%	-8.7%	-19.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	21	-33.2	-106.1	-126.7	-136.6	-60	-222.9	164.2	301	-81.3	-189.8
Op. Profit Mgn % ⓘ	20.1	-22.5	-39	-67.7	-310	-79.1	-397.7	-53.4	-135.5	-88.7	-680.8
Net Profit Mgn % ⓘ	15.6	-25.4	-43.3	-66.5	-299.2	-78.9	-402.7	-60.7	-150.3	-92.6	-683.7
Debt to Equity ⓘ	0	0	1.9	0	0	0	-3.6	-1.4	-0.4	0	-
Working Cap Days ⓘ	161	200	163	210	641	254	554	175	351	339	335
Cash Conv. Cycle ⓘ	-63	-80	-130	-170	-113	-272	-254	-119	-60	-85	3

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 45.95%

Return on Equity is Poor

Sales growth is not so good in last 4 quarters at -55.95%

Latest Financials - Sun Pharma Advanced Research Company Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-12.7	-12.6
TTM Sales (₹ Cr.)	60.1	60.1
BVPS (₹.) ⓘ	-2.5	-2.4
Reserves (₹ Cr.) ⓘ	-112	-110
P/BV ⓘ	-84.01	-86.39
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	196.45 / 474.00
All Time Low / High (₹)	38.44 / 593.93
Market Cap (₹ Cr.)	6,693
Equity (₹ Cr.)	32.5
Face Value (₹)	1
Industry PE ⓘ	45.3

Management X-Ray of Sun Pharma Adv. Res:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

2.18

1.65

1.02

2.78

* Pledged shares as % of Promoter's holding (%)

Valuation of Sun Pharma Adv. Res

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sun Pharma Adv. Res

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	156	161	181	78	183	77	253	137	239	76
Operating Expenses ⓘ	191	224	304	321	334	387	388	324	453	479
Manufacturing Costs	23	31	34	37	23	36	214	139	186	146
Material Costs	0	0	0	0	0	0	0	0	0	0
Employee Cost	46	57	84	101	81	93	92	98	107	119
Other Costs ⓘ	122	137	185	183	230	258	82	87	160	214
Operating Profit ⓘ	-35	-63	-123	-243	-151	-310	-135	-187	-214	-404
Operating Profit Margin (%)	-22.5%	-39.2%	-67.8%	-310.0%	-82.7%	-403.0%	-53.4%	-136.0%	-89.6%	-534.0%
Other Income ⓘ	3	3	14	5	14	10	5	7	11	29
Interest ⓘ	0	2	2	0	0	3	11	13	8	2
Depreciation ⓘ	7	8	8	8	8	9	11	10	12	12
Exceptional Items ⓘ	0	0	0	49	0	0	0	0	0	0
Profit Before Tax ⓘ	-40	-70	-119	-197	-145	-312	-151	-203	-223	-388
Tax ⓘ	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-40	-70	-119	-197	-145	-312	-151	-203	-223	-388
PAT Margin (%)	-25.4%	-43.4%	-65.8%	-251.0%	-79.5%	-406.0%	-59.7%	-148.0%	-93.2%	-513.0%
Adjusted EPS (₹)	-1.7	-3.0	-4.8	-7.9	-5.6	-11.9	-5.8	-7.5	-6.9	-12.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	100	30	158	93	296	-19	-168	-203	513	125
Share Capital ⓘ	24	24	25	25	26	26	26	27	32	32
Reserves ⓘ	76	6	133	68	270	-45	-194	-230	480	92
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	4	55	3	2	1	66	193	0	0	47
Long Term Debt	3	3	2	2	1	6	113	0	0	0
Short Term Debt	0	52	0	0	0	60	80	0	0	47
Trade Payables	27	58	94	102	83	159	91	72	148	150
Others Liabilities ⓘ	16	23	21	116	18	66	114	411	169	165
Total Liabilities ⓘ	147	167	277	313	398	273	230	280	830	486
Fixed Assets
Gross Block	96	107	77	67	80	136	123	133	146	152
Accumulated Depreciation	30	37	8	15	23	32	32	41	40	49
Net Fixed Assetsⓘ	67	70	69	52	58	104	91	92	106	103
CWIP ⓘ	0	1	1	3	24	32	5	26	27	44
Investmentsⓘ	0	0	10	108	211	8	6	12	291	2
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	20	9	39	18	10	16	18	28	33	16
Cash Equivalents ⓘ	17	13	70	1	1	0	9	1	112	155
Others Assetsⓘ	43	74	87	131	95	112	101	121	262	167
Total Assets ⓘ	147	167	277	313	398	273	230	280	830	486

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-41	-44	-128	-183	-172	-211	-152	-208	-69	-429
PBT ⓘ	-40	-70	-119	-246	-145	-312	-151	-203	-223	-388
Adjustment ⓘ	5	9	-1	4	-22	9	49	17	7	-11
Changes in Working Capital ⓘ	-4	30	13	20	-0	102	-48	-26	141	-26
Tax Paid ⓘ	-3	-14	-21	-10	-5	-10	-2	5	5	-4
Cash Flow From Investing Activity ⓘ	53	-13	-7	-105	-102	155	2	-29	-548	391
Capex	-8	-12	-8	-18	-13	-54	-1	-25	-15	-26
Net Investments	7	0	-9	-88	-93	209	3	-5	-535	395
Others ⓘ	54	-1	11	1	3	0	0	0	2	22
Cash Flow From Financing Activityⓘ	-1	51	194	224	274	55	159	229	617	43
Net Proceeds from Shares ⓘ	0	2	250	133	367	0	0	167	0	0
Net Proceeds from Borrowing ⓘ	-1	-1	-1	0	-1	0	106	0	0	0
Interest Paid ⓘ	0	-2	-3	0	0	-2	-8	-14	-8	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	51	-52	91	-92	57	61	77	625	44
Net Cash Flow ⓘ	11	-7	60	-63	0	0	9	-8	-1	4

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-33.17	-109.16	-127.4	-156.84	-74.72	N/A	N/A	N/A	-143.72	-121.73
ROCE (%)	-31.74	-71.37	-94.66	-113.05	-59.95	N/A	N/A	N/A	-69.44	-112.88
Asset Turnover Ratio	0.93	1.03	0.82	0.27	0.51	0.23	1.01	0.54	0.43	0.11
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	56	33	48	132	28	62	24	60	46	117
Inventory Days	0	0	0	0	0	0	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	0

Sun Pharma Advanced Research Company Ltd Stock News

Sun Pharma Advanced Research Company Ltd FAQs

What is the share price of Sun Pharma Adv. Res?

Company share prices are keep on changing according to the market conditions. The closing price of Sun Pharma Adv. Res on 08-Nov-2024 00:00 is ₹206.2.

What is the market cap of Sun Pharma Adv. Res?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 08-Nov-2024 00:00 the market cap of Sun Pharma Adv. Res stood at ₹6,693.3.

What is the P/E ratio of Sun Pharma Adv. Res?

The latest P/E ratio of Sun Pharma Adv. Res as of 08-Nov-2024 00:00 is 0.00.

What is the P/B ratio of Sun Pharma Adv. Res?

The latest P/B ratio of Sun Pharma Adv. Res as of 08-Nov-2024 00:00 is -84.01.

What is the 52-week high and low of Sun Pharma Adv. Res?

The 52-week high of Sun Pharma Adv. Res is ₹474.0 and the 52-week low is ₹196.4.

What is the TTM revenue of Sun Pharma Adv. Res?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Adv. Res is ₹60.09 ( Cr.) .

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

2006: SPARC is founded in Vadodara, India
2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
2012: 1st NDA filed with USFDA for Elepsia XR
2012: Raised Rs. 200 crore through Rights Issue
2013: Filed NDA for Xelpros with USFDA
2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
2015: Entered into research collaboration in the field of Oncology with US University
2015: Launched Bevetex (PICS) in India
2016: Raised Rs. 250 crore through Rights Issue
2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications